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Safety of 2'-O-fucosyllactose as a 
novel food ingredient pursuant to 
Regulation (EC) No 258/97 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 
Abstract 
Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition 
and Allergies (NDA) was asked to deliver an opinion on 2'-O-fucosyllactose as a novel food ingredient 
(NFI) submitted pursuant to Regulation (EC) No 258/97 of the European Parliament and of the 
Council, taking into account the comments and objections of a scientific nature raised by Member 
States. 2'-O-fucosyllactose (2'-FL) is a synthetic trisaccharide, which is intended to be used in infant 
and follow-on formulae, foods for special medical purposes for infants and young children, and other 
foods for infants and young children, as well as in foods or food supplements for adults. The 
information provided on the potential mutagenicity of 2'-FL does not raise safety concerns as regards 
the genotoxicity of this NFI. Based on the observations from a sub-chronic 90-day toxicity study in 
rats, the Panel considers that the no observed adverse effect level is 2 000 mg/kg body weight per 
day. The applicant provided a double-blind, randomised, controlled clinical trial on the effects of 2’-FL 
consumed in combination with another oligosaccharide (lacto-N-neotetraose (LNnT)) in infants. The 
Panel concludes that 2’-FL is safe for infants (up to one year of age) when added to infant and 
follow-on formulae, in combination with LNnT, at concentrations up to 1.2 g/L of 2’-FL and up to 
0.6 g/L of LNnT, at a ratio of 2:1 in the reconstituted formulae; is safe for young children (older than 
one year of age) when added to follow-on and young-child formulae, at concentrations up to 
1.2 g/L of 2’-FL (alone or in combination with LNnT, at concentrations up to 0.6 g/L, at a ratio of 2:1). 
The Panel also concludes that 2’-FL is safe when added to other foods at the uses and use levels 
proposed by the applicant. 
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Summary 
Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition 
and Allergies (NDA) was asked to deliver an opinion on 2'-O-fucosyllactose as a novel food ingredient 
submitted pursuant to Regulation (EC) No 258/97 of the European Parliament and of the Council, 
taking into account the comments and objections of a scientific nature raised by Member States. The 
assessment follows the methodology set out in Commission Recommendation 97/618/EC of 29 July 
1997 concerning the scientific aspects and the presentation of information necessary to support 
applications for the placing on the market of novel foods and novel food ingredients (NFIs) and the 
preparation of initial assessment reports under Regulation (EC) No 258/97. The assessment is based 
on the data supplied in the original application, the initial assessment by the competent authority of 
Ireland, the concerns and objections of the other Member States and the responses of the applicant. 
2'-O-fucosyllactose (2’-FL) is a synthetic trisaccharide consisting of L-fucose, D-galactose and 
D-glucose, which is produced by using L-fucose and D-lactose as starting raw materials. The NFI is 
intended by the applicant to be used in infant and follow-on formulae, foods for special medical 
purposes for infants and young children, and other foods for infants and young children. The NFI is 
also intended to be used in foods or food supplements for adults. The Panel considers that the 
information provided on the specifications, the data from batch testing and the production process do 
not raise safety concerns.  
Based on food consumption data of EFSA for infants and the use level of the NFI (2.4 g/L) proposed 
by the applicant, 2’-FL intakes from infant formula would result in about 2.5 g per day and about 
418 mg/kg body weight, respectively, at the 95th percentile for a 3-month-old infant weighing 6 kg. 
According to the intake estimate provided by the applicant based on individual consumption data from 
the UK, 2’-FL intakes from infant formula could lead to an intake of about 670 mg/kg body weight per 
day at the 95th percentile for infants aged from 4 to 6 months. 
For other population groups, the applicant estimated in a tiered approach, intakes by using the EFSA 
Food Additive Intake Model tool based on summary statistics of consumption data of the EFSA 
Comprehensive Food Consumption Database. For a refined intake estimate, the applicant used 
individual consumption data recorded by the UK National Diet and Nutrition Survey for the 
years 2008–2010. 
Considering that 2’-FL is a naturally occurring trisaccharide that is present in human milk, the history 
of human exposure to 2’-FL is limited primarily to that of breast-fed infants. The Panel notes that the 
proposed maximum intake level of the NFI by infants is within the range of 2′-FL levels found in 
mature breast milk, as reported in the literature, although at the high end of this range. Taking into 
account that there are no indications that the absorption of the NFI may differ from that of 2’-FL from 
breast milk, the Panel considers that the limited amount of NFI that could be absorbed does not raise 
safety concerns. 
The applicant provided three studies on the potential mutagenicity of 2’-FL (a bacterial reverse 
mutation assay, an in vitro mammalian cell gene mutation test and an in vitro micronucleus assay). 
The Panel considers that the information provided does not raise safety concerns as regards the 
genotoxicity of the NFI. 
Based on the observations from a sub-chronic 90-day toxicity study in rats, the Panel considers that 
the no observed adverse effect level is 2 000 mg/kg body weight per day. 
The applicant provided an unpublished study report on a double-blind, randomised, controlled clinical 
trial on the effects of a combination of two oligosaccharides, 2’-FL and lacto-N-neotetraose (LNnT), 
which are both under safety assessment as NFIs, in infants. This study reported that the weight gain 
of infants who consumed the formula with added 2’-FL and LNnT was not inferior to the weight gain 
of infants who were fed the control formula up to four months of age. The results on stool endpoints 
and the reported changes in the composition of microbiota in infants consuming the combination of 
the two oligosaccharides do not raise safety concerns for the studied combination. The Panel 
considers that this study can be used to draw conclusions on the safety of this combination at the 
concentrations tested (i.e. 1.0–1.2 g/L of 2’-FL and 0.5–0.6 g/L of LNnT for reconstituted formula). 
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Noting that complementary feeding of infants and young children results in an increasingly diversified 
diet, the Panel considers that the potential impact of the addition of 2’-FL alone (without LNnT) or in 
combination with LNnT on the development of the microbiota diminishes with the proportion of 
complementary feeding and with age. The Panel therefore considers that 2’-FL alone or in 
combination with LNnT added at the proposed concentration in foods intended for children older than 
one year of age, does not raise safety concerns.  
The applicant also provided an unpublished study report on a placebo-controlled, double-blind, 
parallel, dose-response trial, in healthy adults who were randomised to consume either 2’-FL or LNnT, 
alone or in different combinations, or placebo for two weeks. This study showed that participants who 
consumed daily 20 g of 2’-FL reported a significant increase in nausea, rumbling, bloating, passing 
gas, diarrhoea, loose stools and urgency compared with the placebo group, while, for subjects 
consuming 10 g of 2’-FL per day, these effects were not observed. Considering the highest estimated 
95th percentile daily intake of 2’-FL of 75 mg/kg body weight and 5 g per person, respectively, in 
women of child-bearing age plus the maximum intended daily intake from food supplements of 3 g, 
2’-FL intakes in this population group could reach up to 8 g per day. 
The Panel concludes that the NFI, 2’-FL, is safe for infants (up to one year of age) when added to 
infant and follow-on formulae, in combination with LNnT, at concentrations up to 1.2 g/L of 2’-FL and 
up to 0.6 g/L of LNnT, at a ratio of 2:1 in the reconstituted formulae; is safe for young children (older 
than one year of age) when added to follow-on and young-child formulae, at concentrations up to 
1.2 g/L of 2’-FL (alone or in combination with LNnT, at concentrations up to 0.6 g/L, at a ratio of 2:1). 
The Panel also concludes that 2’-FL is safe when added to other foods at the uses and use levels 
proposed by the applicant. 
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1. Introduction  
 Background and Terms of Reference as provided by the European 1.1.
Commission 
On 23 June 2014, the company Glycom A/S submitted a request in accordance with Article 4 of the 
Novel Food Regulation (EC) No 258/971 to place on the market 2'-O-fucosyllactose (2'-FL) as a novel 
food ingredient. 
On 3 October 2014, the competent authority of Ireland forwarded to the Commission its initial 
assessment report, which came to the conclusion that 2'-FL meets the criteria for acceptance of a 
novel food defined in Article (3)1 of Regulation (EC) No 258/97. 
On 9 October 2014, the Commission forwarded the initial assessment report to the other Member 
States. Several Member States submitted comments or raised objections.  
In consequence, a decision is now required by the Commission under Article 7(1) of Regulation (EC) 
No 258/97. 
The concerns of a scientific nature raised by the Member States can be summarised as follows: 
 The product specification allows for a lower level of purity, compared to the product that was 
used for actual experiments (≥ 95 % as opposed to > 99 % in the 90 day toxicity study in rats). 
The applicant should make sure that the actual product does not contain more contaminants than 
the test article used to obtain the necessary experimental safety data, in order to vouch for the 
validity of the safety data recorded in the dossier. 
 Regarding the microbiological parameters in the specification, specific conditions for several types 
of foods are more extensively described in Regulation 2073/2005, as amended. In particular, this 
has implications for the sampling plans for final products that would be formulated to contain 
2’-FL. 
 Clarification was requested on the accreditation of the laboratories which carried out the analyses.  
 A detailed chemical characterisation of the product is needed. 
 Given that an organometallic catalyst is used in the manufacturing process, it would be useful for 
heavy metals analyses to be included as part of the quality assurance procedure. 
 In the dossier, it is stated that the intake of 2’-FL in the form of food supplements would not be 
expected to influence the overall daily intake. However, one should consider the possibility for 
combined intake of 2’-FL from food supplements and other food uses specified in the dossier as a 
realistic scenario, that could more or less double the daily intake for high-level users. 
 Intake of large quantities of indigestible carbohydrates may produce laxative effects. As there are 
no human studies on 2'-FL, apart from experience with infants who have been breast-fed, nothing 
can be said about the quantities of 2'-FL which may produce laxative effects. 
 Considering that the novel food ingredient may also be consumed by more vulnerable individuals 
such as those with conditions that result in a ‘leaky gut’, any further information could be provided 
on any possible consequences that may be associated with an increased level of absorption of the 
novel food ingredient. 
 The potential for genotoxicity was only assessed in two in vitro tests for mutagenicity. A test for 
potential clastogenic activity is lacking (in vitro micronucleus test or in vitro chromosome 
aberration test). The absence of genotoxicity for this 2’-FL-preparation would only be 
demonstrated sufficiently, upon obtaining a favourable outcome in such study.  
 No data on human trials using the applicant’s 2’-FL are reported in the dossier. Whereas the 
application in infant formula and follow-on formula would mirror the endogenous presence of 
2’-FL in human milk, the applications for other age groups lack such a basis for comparison of 
                                                          
1 Regulation (EC) No 258/97 of the European Parliament and of the Council of 27 January 1997 concerning novel foods and 
novel food ingredients. OJ L 43, 14.2.1997, p. 1–6. 
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tolerability for 2’-FL ingestion. In particular, this could be relevant for the consumption of 2’-FL in 
concentrated forms, as could be the case for food supplements. 
 Additional information is needed on the reason behind the use of this NFI.  
 
In accordance with Article 29(1)(a) of Regulation (EC) No 178/2002,2 the European Food Safety 
Authority is asked to carry out the additional assessment for 2'-O-fucosyllactose as a novel food 
ingredient in the context of Regulation (EC) No 258/97. 
EFSA is asked to carry out the additional assessment and to consider the elements of a scientific 
nature in the comments raised by the other Member States. 
2. Data and Methodologies  
 Data 2.1.
The assessment of the safety of this NFI is based on data supplied in the original application, the 
initial assessment by the competent authority of Ireland, the concerns and objections of the other 
Member States and the responses of the applicant (see ‘Documentation provided to EFSA’). 
In accordance with Commission Recommendation 97/618/EC,3 2'-O-fucosyllactose (2'-FL) is allocated 
to Class 1.2, i.e. ‘pure chemicals or simple mixtures from non-genetically modified sources; the source 
of the NF has no history of food use in the Community’. The data are required to comply with the 
information required for novel foods of Class 1.2, i.e. structured schemes I, II, IX, X, XI, XII and XIII 
of Commission Recommendation 97/618/EC. In the current opinion, these structured schemes are 
listed in sections 3.1 to 3.8. The applicant’s intention is to use the NFI in infant formula (IF), follow-on 
formula (FOF), foods for special medical purposes for infants and young children, and other foods for 
infants and young children. The applicant also proposed the use of this NFI in foods or food 
supplements for adults. This assessment concerns only risk that might be associated with 
consumption, and is not an assessment of the efficacy of 2'-FL with regard to any claimed benefit.  
 Methodologies 2.2.
The assessment follows the methodology set out in Commission Recommendation 97/618/EC of 
29 July 1997 concerning the scientific aspects and the presentation of information necessary to 
support applications for the placing on the market of novel foods and NFIs and the preparation of 
initial assessment reports under Regulation (EC) No 258/97 of the European Parliament and of the 
Council. 
  
                                                          
2 Regulation (EC) No 178/2002 of the European Parliament and of the Council of 28 January 2002 laying down the general 
principles and requirements of food law, establishing the European Food Safety Authority and laying down procedures in 
matters of food safety. OJ L 31, 1.2.2002, p. 1–24. 
3 97/618/EC: Commission Recommendation of 29 July 1997 concerning the scientific aspects and the presentation of 
information necessary to support applications for the placing on the market of novel foods and novel food ingredients and the 
preparation of initial assessment reports under Regulation (EC) No 258/97 of the European Parliament and of the Council. OJ 
L 253, 16.9.1997, p. 1–36. 
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3. Assessment 
 Specification of the Novel Food Ingredient (NFI) 3.1.
The NFI is 2'-O-fucosyllactose (2’-FL), a synthetic oligosaccharide produced using L-fucose and 
D-lactose as starting raw materials (section 3.2).  
2’-FL is a trisaccharide consisting of L-fucose, D-galactose and D-glucose (chemical formula: C18H32O15; 
molecular weight: 488.44 Da; CAS No 41263-94-9) (Figure 1). The structure can be described as 
consisting of the monosaccharide L-fucose and the disaccharide D-lactose, which are linked by an 
α-(12) bond to form the trisaccharide. 
 
 
Figure 1:  Molecular structure of 2’-FL 
The IUPAC name of 2’-FL is α-L-fucopyranosyl-(12)-β-D-galactopyranosyl-(14)-D-glucopyranose. 
Alternative names are 2’-O-L-fucosyl- D-lactose; fucosyl-α-1,2-galactosyl-β-1,4-glucose; and Fuc-α-
(12)-Gal-β-(14)-Glc. 
2’-FL has been characterised by spectroscopic techniques (e.g. 1H-, 13C-, and 2D-nuclear magnetic 
resonance (NMR)), mass spectrometry (MS) and high-performance liquid chromatography (HPLC). 
The chemical and spectroscopic data provided by the applicant are consistent with the structure 
proposed (Ishizuka et al., 1999). The applicant demonstrated that the NFI is identical to the 2’-FL that 
is present in human breast milk by comparison with an authentic specimen. In response to a comment 
from a Member State, the applicant provided additional data on the chemical structure of 2’-FL. 
The product specifications, as proposed by the applicant, are presented in Table 1. 
Analytical results from five batches of the NFI, which complied with the product specifications, are 
presented in Table 2. 
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Table 1:  Specifications for 2’-FL as proposed by the applicant 
Parameter Specification Method 
Appearance  Powder  MSZ ISO 6658:2007 
Colour  White to off-white  MSZ ISO 6658:2007 
Identification  RT of standard ± 3%  Glycom method HPLC-202-2C4-003  
2’-FL (water free)  Min. 95.0 % Glycom method HPLC-202-C4-002 
D-lactose(a) Max. 1.0  w/w % Glycom method HPAEC-202-001  
L-Fucose(a) Max. 1.0  w/w %   Glycom method HPAEC-202-001  
Difucosyl-D-lactose isomers(a) Max. 1.0  w/w %  Glycom method HPAEC-202-001  
2’-Fucosyl-D-lactulose(a) Max. 0.6 w/w % Glycom method HPLC-202-2C4-003   
pH (20°C, 5 % solution)  3.2 to 7.0  EP method  
Water Max. 9.0%  Karl-Fischer (EP 2.5.32)  
Ash, sulphated  Max. 0.2%  EP 2.4.14  
Acetic acid(b)  Max. 0.3%  MSZ EN ISO 10304-1:2009  
Residual solvents Max. 50 mg/kg singly  
Max. 200 mg/kg in combination 
EP GC 2.4.24  
Residual proteins(c)  Max. 0.01 %(d) 
 
 Bradford protein assay 
Palladium Max. 0.1 mg/kg ICP-MS EPA 6020A:2007 
Nickel Max. 3.0 mg/kg ICP-MS EPA 6020A:2007 
Microbiological specifications 
Salmonella  Absent in 25 g  MSZ-EN-ISO 6579:2006  
Aerobic mesophilic total count Max. 500 CFU/g  MSZ-EN-ISO 4833:2003  
Enterobacteriaceae  Absent in 10 g  MSZ-ISO 21528-2:2007  
Cronobacter (Enterobacter) 
sakazakii  
Absent in 10 g  ISO-TS 22964:2006  
Listeria monocytogenes  Absent in 25 g  MSZ-EN-ISO 11290-1:1996, 
1998/A1:2005  
Bacillus cereus  Max. 50 CFU/g  MSZ-EN-ISO 7932:2005  
Yeasts  Max. 10 CFU/g  MSZ-ISO 7954:1999  
Moulds  Max. 10 CFU/g  MSZ-ISO 7954:1999  
Residual endotoxins(c) Max. 10 EU/mg(d) EP 2.6.14  
CFU: colony forming units; EP: European Pharmacopoeia; EPA: Environmental Protection Agency; EU: endotoxin units; GC: gas 
chromatography; HPLC: high-performance liquid chromatography; HPAEC: high-performance anion exchange chromatography; 
ICP-MS: inductively coupled plasma mass spectrometry; max.: maximum; min.: minimum; RT: retention time 
(a): These specifications refer to the water-free compound 
(b): As free acid and/or sodium acetate 
(c): Specifications for residual proteins and endotoxins are included to allow control on any impurity stemming from potential 
raw materials produced from alternative production processes (i.e. fermentation) and to provide reassurance that 2’-FL 
produced through Glycom’s method of manufacture is controlled for residual levels of proteins and endotoxins. 
(d): Specification may be amended (i.e. lowered) should additional data become available in the future. 
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Table 2:  Analyses of five batches of the NFI 
 
Parameter  
 
Specification  
Batch results 
L06112K PSD4201  
31210/166 
PSD4201  
31210/167 
PSD4201  
31210/168 
PSD4201  
31210/169 
Appearance  Powder  Powder  Powder  Powder  Powder  Powder  
Colour  White to off-
white  
White  White  White  White  White  
Identification  RT of main 
component 
corresponds to 
RT of standard 
± 3%  
Complies  Complies  Complies  Complies  Complies  
2’-FL 
(water free) (%) 
 
Min. 95.0 % 
 
96.9  
 
97.0  
 
98.2  
 
97.0  
 
97.8  
D-Lactose (%)(a) Max. 1.0 w/w % 0.07 0.09 0.10 0.15 0.18 
L-Fucose (%)(a) Max. 1.0 w/w % < LOR(f) 0.03 0.04 0.06 0.08 
Difucosyl-D-lactose 
isomers (%)(a) 
Max. 1.0 w/w % < LOR(f) < LOR(f) < LOR(f) < LOR(f) < LOR(f) 
2’-Fucosyl-D-
lactulose (%)(a) 
Max. 0.6 w/w % 0.06 0.42 0.49 0.35 0.30 
pH (20°C, 5% 
solution)  
3.2 to 7.0 6.2 3.9 3.9 3.7 3.6 
Water (%)  Max. 9.0  0.3  2.8  3.2  3.2  3.1  
Ash, sulphated (%)  Max. 0.2  0.15 < 0.01 0.07 0.05 0.05 
Acetic acid (%)(b) Max. 0.3  0.003 0.05 0.05 0.03 0.03 
Residual solvents 
Singly (mg/kg)  
Combination 
(mg/kg)  
 
Max. 50  
Max. 200 
 
n/a(d) 
n/a(d) 
 
< 10 
< 70 
 
< 10 
< 70 
 
< 10 
< 70 
 
< 10 
< 70 
Residual proteins 
(%)(e) 
Max. 0.01(e) < LOQ(g) < LOQ(g) < LOQ(g) < LOQ(g) < LOQ(g) 
Palladium (mg/kg) Max. 0.1  < 0.1 < 0.1 < 0.1 < 0.1 < 0.1 
Nickel (mg/kg) Max. 3.0 < 0.1 0.2 0.2  0.3   0.3 
Microbiological specifications  
Salmonella  Absent in 25 g  Complies  Complies  Complies  Complies  Complies  
Aerobic mesophilic 
total count  
Max. 500 CFU/g  < 10  < 10  < 10  < 10  < 10  
Enterobacteriaceae Absent in 10 g  Complies  Complies  Complies  Complies  Complies  
Cronobacter 
(Enterobacter) 
sakazakii  
Absent in 10 g  Complies  Complies  Complies  Complies  Complies  
Listeria 
monocytogenes  
Absent in 25 g  n/a  Complies  Complies  Complies  Complies  
Bacillus cereus  Max. 50 CFU/g  n/a  < 10  < 10  < 10  < 10  
Yeasts  Max. 10 CFU/g  Complies  Complies  Complies  Complies  Complies  
Moulds  Max. 10 CFU/g  Complies  Complies  Complies  Complies  Complies  
Residual 
endotoxins(e) 
Max. 10 EU/mg(e) < LOR(c)  < LOR(c) < LOR(c) < LOR(c) < LOR(c) 
CFU: colony forming units; EU: endotoxin units; HPLC: high-performance liquid chromatography; LOQ: limit of quantification; 
LOR: level of reporting; max., maximum; min.: minimum; n/a: not applicable; RT: retention time 
(a): These specifications refer to the water-free compound. 
(b): In the form of free acetic acid and/or sodium acetate. 
(c): LOR = 0.01 EU/mg. 
(d): Not applicable to specifications; batch L06112K was not spray dried. 
(e): Specifications for residual proteins and endotoxins are included to allow control on any impurity stemming from potential 
raw materials produced from alternative production processes (i.e. fermentation) and to provide reassurance that 2’-FL 
produced through Glycom’s method of manufacture is controlled for residual levels of proteins and endotoxins. 
(f): LOR = 0.03 % 
(g): LOQ = 0.0018 w/w %  
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The NFI is a white to off-white powder. In response to a comment from a Member State on the level 
of purity of 2’-FL, the applicant indicated that the specification is set at a minimum of 95 % owing to 
the standard deviation of the assay method (around 2 %), which depends upon the hygroscopicity of 
2’-FL and the method used for detection (charged aerosol detection). Taking into account the results 
of the analyses of five batches (Table 2), the applicant considered that the limit of 95 % is justified.  
Upon a request by EFSA for clarification of the impurities of the NFI, the applicant proposed to include 
additional specifications for the residual starting materials (D-lactose and L-fucose) and the other 
carbohydrate-type by-products, difucosyl-D-lactose isomers and 2’-O-fucosyl-D-lactulose, which are 
formed during the manufacturing process. Only one of the difucosyl-D-lactose isomers, 
3,2’-O-difucosyllactose, is naturally present in human milk (Erney et al., 2001), whereas the 
2’,6’-O-difucosyllactose has not been reported to be present in human milk so far. 
2’-O-Fucosyl-D-lactulose is an isomer of 2’-FL, arising from the isomerisation of the terminal glucose 
moiety of 2’-FL to fructose.  
The specifications for residual solvents are provided for single and combined solvents, with maximum 
limits of 50 mg/kg and 200 mg/kg, respectively. The applicant confirmed that all solvents used in the 
process are used as processing aids. The applicant clarified that toluene, which is not used as a 
solvent during production, is formed as a volatile product of the hydrogenation reaction of 
benzyl-2’-FL and is removed during the spray drying step (Section 3.2). The applicant indicated that 
toluene is controlled by the internal specifications. Taking into consideration Joint FAO/WHO Expert 
Committee on Food Additives (JECFA) and European Medicines Agency (EMA) guidance for 
pharmaceuticals on residual solvents (ICH, 2011; EMA, 2014), the Panel considers that residual 
solvents do not raise safety concerns. 
The protein content is specified at a maximum level of 0.01 %. Batch analyses indicate that protein 
content is below the limit of quantification (i.e. 0.0018 w/w %). 
In response to a comment from a Member State, the applicant indicated that Palladium residue is 
maintained at levels below 0.1 mg/kg, as confirmed by the results of the batch analyses (Table 2). 
Nickel is also included in the product specifications (< 3.0 mg/kg), but at levels much lower than the 
Permitted Daily Exposure levels recommended by EMA for medicinal products. The potential presence 
of other metals is controlled by internal specifications. 
Microbiological contaminants are also controlled by specifications. In response to a comment from a 
Member State, the applicant indicated that the procedures applied to the NFI are compliant with the 
hazard analysis and critical control points (HACCP), which are described in Regulation 2073/2005. 
In response to a comment from a Member State, the applicant indicated that analytical measurements 
were performed using internationally recognised methods in accredited external laboratories. As no 
internationally recognised methods exist for the analysis of 2’-FL or 2’-FL-derived carbohydrates, 
methods were developed by the applicant and validated under Good Laboratory Practices (GLP). 
In addition to the product specifications reported in Table 1, the applicant provided further internal 
product specifications, which have been claimed confidential. The internal product specifications 
include maximum limits for raw materials, intermediate products and processing aids used in the 
production process.  
The Panel considers that the information provided on the composition, specification and data from 
batch testing do not raise safety concerns. 
3.1.1. Stability of the NFI 
A 6-month accelerated stability study (40 °C, 75 % relative humidity) has been performed on 
crystalline 2’-FL obtained from a single batch. Samples for chemical and microbiological analyses were 
packed into polyethylene bags (primary packaging material), and polyethylene/aluminium/polyester 
triple layer foil bags (secondary packaging material). 2’-FL was analysed by HPLC and water content 
was analysed by Karl Fischer titration.  
The low water content after six months of storage (0.1 %) indicates that the packaging is appropriate 
for protecting 2’-FL from water absorption. Lactose, the potential degradation product of 2’-FL, was 
below 0.1 % after three and six months of storage. No unknown degradation products were observed 
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in the HPLC chromatogram. These results indicate that 2’-FL is stable and does not degrade when 
stored under accelerated conditions for periods of up to six months. Furthermore, microbiological 
purity was maintained throughout the duration of the 6-month study. 
A 5-year long-term stability study (25 °C, 60 % relative humidity) on one batch of crystalline 2’-FL 
was on-going at time of the submission of this dossier. The applicant provided the analytical results 
obtained up to the 36-month point of this long-term stability study for samples of 2’-FL that were 
packaged in the same way as in the previous study. 
The applicant indicated that no significant changes were observed in the value for 2’-FL for up to 36 
months of storage. An increase in water content was observed by 18 months of storage (0.5 % vs. 
0.1 % at time 0), which was maintained throughout the 36 months of storage (0.5 % at 24 months 
and 0.4 % at 36 months). Lactose, the potential degradation product of 2’-FL, was below 0.1 % at all 
time-points up to 36 months of storage. No unknown degradation products were observed in the 
HPLC chromatogram at any time point during the 36 months of storage. These results indicate that 
crystalline 2’-FL is stable and does not degrade when stored at a temperature of 25 °C for periods of 
up to 36 months. Microbiological purity was maintained throughout the duration of the 36 months. 
Based on the available data, the shelf-life of crystalline 2’-FL, as proposed by the applicant, is 
36 months when stored at room temperature protected from humidity. 
The Panel notes that the stability experiments have been performed on a ‘crystalline’ product which 
contains 0.1 % water, whereas the NFI is a ‘powder’ with a water content of up to 9 %. However, 
despite this limitation, the Panel considers that, if protected by adequate packaging, the NFI is 
sufficiently stable. 
3.1.2. Stability under the intended conditions of use  
The NFI is intended to be used as an ingredient in IF, FOF, baby foods and a range of food products 
(Section 3.3). The applicant assessed the stability of the NFI added to IF (stored for three years at 
temperatures of 4, 20, 30 and 37 °C), yoghurt (stored for 21 days at 4 °C), citrus juice (stored for 28 
days at 4 °C) and ready-to-drink flavoured milk (stored for 14 days (pasteurised) or 28 days 
(ultra-high temperature (UHT)-treated) at 4 °C). 2’-FL was added during the production process of 
these foods, to assess the effects of these processing on the NFI, as well as the stability of the NFI in 
storage. No significant losses of 2’-FL were observed in any of the conditions tested, which included 
pasteurisation and UHT treatments.  
The Panel considers that the data provide sufficient information with respect to the stability of the 
NFI. 
 Effect of the production process applied to the NFI  3.2.
2’-FL is produced by chemical synthesis through a two-stage manufacturing process.   
In the first stage, the source raw materials L-fucose and D-lactose are used to produce the 
intermediate benzyl-2’-FL. D-Lactose complies with the specifications set in the European 
Pharmacopeia, whereas L-fucose is produced by the applicant through a controlled process. L-Fucose 
and D-lactose are derivatised and protected to give the stereo- and regio-selective 
α -(12)-glycosylation reaction. Benzyl-2’-FL is a high-quality and high-purity material, which is 
manufactured through a controlled process where all batches of benzyl-2’-FL are controlled for 
conformity to the specifications.  
In the second stage, the intermediate benzyl-2’-FL is used to produce the final powdered product 
2’-FL through a series of steps which include hydrogenation, purification and spray drying.  
2’-FL is manufactured in compliance with good manufacturing practice. The applicant indicates that 
specifications are set according to HACCP principles, as defined by Regulation (EC) No 852/2004 and 
conformity is monitored by certificates of analysis at each key stage of the production process. 
The Panel considers that the production process is sufficiently described and does not raise safety 
concerns. 
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 Anticipated intake/extent of use of the NFI 3.3.
3.3.1. Uses for infants and young children 
The applicant intends to market 2’-FL as an ingredient in IF and FOF, including formulae for special 
medical purposes and other foods for infants and young children (Table 3). The proposed maximum 
use levels in all other food categories are based on the applicant’s consideration of providing a similar 
intake to that of 2’-FL from mature breast milk on a mg/kg body weight basis. 
Table 3:  Proposed food uses for 2’-FL for infants and young children  
Food category name Proposed maximum use level 
Foods for infants and young children  
Infant formulae as defined by Commission Directive 
2006/141/EC4 
2.4 g/L of reconstituted formula 
Follow-on formulae as defined by Directive 2006/141/EC4 2.4 g/L of reconstituted formula 
Processed cereal-based foods and baby foods for infants and 
young children as defined by Commission Directive 
2006/125/EC5 
1.2 g/100 g for solid foods 
Other foods for young children  1.2 g/100 g for solid foods 
1.2 g/L for beverages as consumed 
(2.4 g/L for young-child formula) 
Dietary foods for infants and young children for special 
medical purposes as defined by Commission Directive 
1999/21/EC6 and special formulae for infants 
As specified on a case-by-case basis in 
accordance with Commission Directive 
1999/21 
 
For infants aged 0 to 6 months, the estimated intake of 2’-FL was calculated from the use of 2 -FL in 
IF alone, under the assumption that it would be the only source of 2’-FL in this population group. The 
daily intake of liquid IF has been estimated to be 1 060 mL/day for infants aged 0 to 6 months, based 
on food consumption data used by EFSA (EFSA AFC Panel, 2006). This food intake scenario used by 
EFSA was based on a 3-month-old infant weighing 6.1 kg consuming 174 mL/kg body weight per day 
of IF at the 95th percentile. Assuming an intended use level of 2.4 g 2’-FL/L formula, the 95th 
percentile daily intake of 2’-FL from its use in IF alone is estimated to be 2.5 g/day (418 mg/kg body 
weight per day) in infants aged 0 to 6 months.  
For infants aged 4 to 17 months, the applicant estimated intakes of 2’-FL from the consumption of IF 
and other infant-specific foods and beverages based on data available from the recent UK Diet and 
Nutrition Survey on Infants and Young Children (DNSIYC) conducted in 2011 (NatCen Social Research 
et al., 2013). Food consumption was estimated through a 4-day dietary diary. Intake estimates of 
2’-FL were calculated based on the proposed use levels expressed in Table 3 for the category ‘Foods 
for Infants and Young children’. These intakes are based on the intake of infant specific foods only for 
this food category. The percentage of users of foods from this category was high among all age 
groups evaluated in the current intake assessment (above 84.7 %), with the highest percentage users 
found among infants aged 4 to 6 months (98.1 %) Large user percentages within a population group 
typically lead to similar results for the all-person and all-user consumption estimates. Consequently, 
only the all-user intake results will be discussed in detail. 
It was determined that infants aged 4 to 6 months have the greatest mean all-user intakes of 2’-FL on 
an absolute basis of 2.75 g per day, while infants aged 7 to 12 months had the highest 95th 
percentile all-user intakes at 6.12 g per day, respectively (Table 4). Young children aged 13 to 
17 months had the lowest mean and 95th percentile all-user intakes at 1.28 and 3.80 g/day, 
respectively. 
                                                          
4 Commission Directive 2006/141/EC of 22 December 2006 on infant formulae and follow-on formulae and amending Directive 
1999/21/EC. OJ L 401, 30.12.2006, p. 1–33. 
5 Commission Directive 2006/125/EC of 5 December 2006 on processed cereal-based foods and baby foods for infants and 
young children. OJ L 339, 6.12.2006, p. 16–35. 
6 Commission Directive 1999/21/EC of 25 March 1999 on dietary foods for special medical purposes. OJ L 91, 7.4.1999, p. 29–36. 
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On a body weight basis, infants aged 4 to 6 months were identified as having the highest mean and 
95th percentile all-user intakes of all groups at 338 and 668 mg/kg body weight per day, respectively. 
Young children aged 13 to 17 months had the lowest mean and 95th percentile all-user intakes at 
118 and 355 mg/kg body weight per day, respectively (Table 5). 
In response to a comment from a Member State on the reason behind the use of this NFI, the 
applicant indicated that the NFI is identical to the 2’-FL that is present in human breast milk.  
Table 4:  Summary of the estimated daily intake of 2’-FL from all proposed food categories(a) in the 
UK by population group, based on data from DNSIYC 2011 
Population 
group 
Age group 
(months) 
Total  
(n) 
All-person 
consumption 
(g/day) 
All-user consumption 
(g/day) 
Mean  95th 
percentile  
% n Mean  95th 
percentile  
Infants 4–6  329 2.70 5.45 98.1 323 2.75 5.49 
Infants 7–12 1 319 2.44 5.98 94.8 1 252 2.58 6.12 
Young children 13–17  1 035 0.87 3.34 67.5 688 1.28 3.80 
Total 4–17 2 683 1.87 5.24 84.7 2 263 2.21 5.50 
(a): For the DNSIYC, only intakes based on the category ‘Foods for infants and young children’ were included in the 
assessment. 
 
Table 5:  Summary of the estimated daily per kg body weight intake of 2’-FL from all proposed food 
categories(a) in the UK by population group, based on data from DNSIYC 2011 
Population 
group 
Age group 
(years) 
Total  
(n) 
All-person 
consumption 
(mg/kg body weight 
per day) 
All-user consumption 
(mg/kg body  
weight per day) 
Mean  95th 
percentile 
% n Mean  95th 
percentile 
Infants 4–6  329 332 666 98.1 323 338 668 
Infants 7–12 1 319 259 636 94.8 1 252 273 641 
Young children 13–17  1 035 79 316 67.5 688 118 355 
Total 4–17 2 683 199 580 84.7 2 263 234 601 
(a): For the DNSIYC, only intakes based on category ‘Foods for infants and young children’ were included in the assessment. 
 
3.3.2. Other food uses for other population groups  
The applicant intends to market 2’-FL as an ingredient in a variety of food products including food 
supplements (Table 6). In a tiered approach the applicant first estimated intakes of the NFI by using 
the EFSA Food Additive Intake Model (FAIM) tool which is based on summary statistics of 
consumption data of the EFSA Comprehensive Food Consumption Database (EFSA, 2012). For a 
refined intake estimate, the applicant used individual consumption data recorded by the UK National 
Diet and Nutrition Survey (NDNS) for the years 2008–2010 (UKDA, 2012). 
The proposed maximum use levels of 2’-FL in all food categories are based on the applicant’s 
consideration of providing similar intakes to those of 2’-FL from breast milk for infants on a mg/kg 
body weight basis.  
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Table 6:  Uses and use levels for 2’-FL (g/kg)(a) proposed by the applicant 
UK NDNS 
food categories 
Food 
classification 
system used by 
the FAIM Tool 
Food category name Suggested 
serving size 
Maximum level per 
serving 
Proposed 
maximum use level  
(g/kg or g/L)(b) 
Dairy products and 
analogues: 
 
Unflavoured 
pasteurised, sterilised 
milk and milk–recipes, 
 
Unflavoured fermented 
milk products, 
 
Flavoured fermented 
milk products, 
 
Dairy analogues. 
1.1 Unflavoured pasteurised and sterilised (including 
UHT) milk 
200 g 1.2 g/L 1.2 
1.2 Unflavoured fermented milk products 125 g 
 
1.2 g/L for beverages. 
 
Other foods:  
1.2–2.4 g/serving 
1.2 g/L for beverages 
 
9.6–19.2 g/kg for 
solids 
1.3 Unflavoured fermented milk products, heat-
treated after fermentation 
1.4 Flavoured fermented milk products including heat-
treated products 
1.8  
 
 
 
Dairy analogues, including beverage whiteners  
200 g 1.2 g/L for beverages 
 
1.2–2.4 g/serving for other 
foods 
1.2 g/L for beverages 
 
6–12g /kg for solids 
3 g 1.2 g per sachet whitener 400 
Cereal bars  7.2 Fine bakery wares. Cereal bars only n/a(c) 1.2 g/100 g 12 
Table top sweeteners 11.4 Table top sweeteners 6 g sachet 1.2 g per sachet 200 
 
Infant formula and 
follow-on formula. 
 
Foods for infants and 
young children,  
 
Dietary foods 
(including powders) for 
weight control diets, 
  
 
Foods suitable for 
people intolerant to 
gluten. 
13.1.1 (d) Infant formulae as defined by  
Commission Directive 2006/141/EC7(e) 
n/a(d) 2.4 g/L of reconstituted 
formula 
2.4 
13.1.2 (d) Follow-on formulae as defined by  
Directive 2006/141/EC7(e) 
n/a(d) 2.4 g/L of reconstituted 
formula 
2.4 
13.1.3 (d) Processed cereal-based foods and baby foods for 
infants and young children as defined by 
Commission Directive 2006/125/EC8(e) 
n/a(c) 1.2 g/100 g for solid foods 12 
13.1.4 (d) Other foods for young children(e) n/a(c) 1.2 g/100 g for solid foods 12 
 n/a(c) 1.2 g/L for beverages as 
consumed 
 
2.4 g/L for young-child 
formula 
1.2  for beverages 
 
2.4 for young-child 
formula 
13.2 Dietary foods for special medical purposes defined 
in Directive 1999/21/EC9  
Case-by-case 
basis 
As specified on a case-by-
case basis in accordance 
Case-by-case basis 
                                                          
7  Commission Directive 2006/141/EC of 22 December 2006 on infant formulae and follow-on formulae and amending Directive 1999/21/EC. OJ L 401, 30.12.2006, p. 1-33. 
8  Commission Directive 2006/125/EC of 5 December 2006 on processed cereal-based foods and baby foods for infants and young children. OJ L 339, 6.12.2006, p. 16-35. 
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UK NDNS 
food categories 
Food 
classification 
system used by 
the FAIM Tool 
Food category name Suggested 
serving size 
Maximum level per 
serving 
Proposed 
maximum use level  
(g/kg or g/L)(b) 
 (excluding products from food category 13.1.5 
‘Dietary foods for infants and young children for 
special medical purposes and special formulae for 
infants’)(f) 
with Commission Directive 
1999/21 
13.3 Dietary foods for weight control diets intended to 
replace total daily food intake or an individual 
meal (the whole or part of the total daily diet)  
250 g drinks 
30 g bars 
1.2 g/meal replacement 4.8 for drinks 
 
40 for bars 
13.4 Foods suitable for people intolerant to gluten as 
defined by Commission Regulation (EC) No 
41/200910 
Bread 
products: 40 g 
 
Pastas: 55 
(unprepared) 
to 110 g 
(prepared) 
1.2–2.4 g/serving 11–60 
Beverages: 
 
Fruit & vegetable juices 
and nectars,  
 
Flavoured drinks, 
 
Coffee, tea (except 
black tea), 
 
Herbal and fruit 
infusions. 
14.1.2 Fruit juices as defined by Directive 2001/112/EC11 
and vegetable juices 
n/a(c) 1.2 g/L 1.2 
14.1.3 Fruit nectars as defined by Directive 
2001/112/EC11 and vegetable nectars and similar 
products 
n/a(c) 1.2 g/L 1.2 
14.1.4 Flavoured drinks  n/a(c) 1.2 g/L 1.2 
14.1.5 Coffee, tea (excluding black tea), herbal and fruit 
infusions, chicory; herbal and fruit infusions and 
chicory extracts; tea, plant, fruit and cereal 
preparations for infusions, as well as mixes and 
instant mixes of these products  
250 1.2–2.4 g/serving 4.8–9.6 
Food supplements as 
defined in Directive 
2002/46/EC12  
17.1 Food supplements supplied in a solid form 
including capsules and tablets and similar forms, 
excluding chewable forms 
n/a(c) 3.0 g per day Maximum intake of 
3.0 g/day(g) 
                                                                                                                                                                                                                                                                                       
9 Commission Directive 1999/21/EC of 25 March 1999 on dietary foods for special medical purposes. OJ L 91, 7.4.1999, p. 29–36. 
10 Commission Regulation (EC) No 41/2009 of 20 January 2009 concerning the composition and labelling of foodstuffs suitable for people intolerant to gluten. OJ L 16, 21.1.2009, p. 3–5. 
11 Council Directive 2001/112/EC of 20 December 2001 relating to fruit juices and certain similar products intended for human consumption. OJ L 10, 12.1.2003, p. 58–66. 
12 Directive 2002/46/EC of the European Parliament and of the Council of 10 June 2002 on the approximation of the laws of the Member States relating to dietary supplements. OJ L 183, 12.7.2002, 
p. 51–57. 
Safety of 2'-O-fucosyllactose 
 
 
 
www.efsa.europa.eu/efsajournal 17 EFSA Journal 2015;13(7):4184 
 
UK NDNS 
food categories 
Food 
classification 
system used by 
the FAIM Tool 
Food category name Suggested 
serving size 
Maximum level per 
serving 
Proposed 
maximum use level  
(g/kg or g/L)(b) 
17.2 Food supplements supplied in a liquid form n/a(c) 
17.3 Food supplements supplied in a syrup-type or 
chewable form 
n/a(c) 
EC: European Commission; EU: European Union; n/a: not applicable 
(a): While it is proposed that 2-FL will be added to these food categories, including ‘Dairy products and analogues’, once placed on the market, all food products with added 2-FL would be 
appropriately reclassified and labelled . 
(b): The proposed maximum use level is presented on a g/kg basis for solids and on a g/L basis for liquids. 
(c): A serving size is not provided on the basis that the use level is specified on a per L/kg basis and not on a per serving basis.  
(d): The suggested serving size for infant formula is according to the manufacturer’s instructions and according to the baby’s age and weight. 
(e): These categories were also assessed using food consumption data from the DNSIYC. 
(f): This category was not included in the UK NDNS intake assessment as these products should be assessed on a case-by-case basis, and are not widely consumed by the general population. 
(g): Food supplements were not included in the combined intake assessment as a maximum of 3.0 g of 2-FL per day through a single supplement dose would be recommended. 
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Mean and high-intake estimates derived with the EFSA FAIM tool are presented in Table 7. A total of 
26 different dietary surveys carried out in 17 different European countries are included in the FAIM 
tool. Mean intake values for the total population are calculated per age group by summing up the 
mean exposures from all contributing food sources in a given survey. High-level values of a given food 
category are calculated either as the 95th percentile of consumers-only, when the number of 
consumers is ≥ 60, or as the mean of consumers only, when the number of consumers is < 60. 
The applicant used the lower and upper ends of the proposed use level ranges per food category for 
the calculation in the FAIM tool. The food categories included in the calculations were dairy products 
and analogues, bakery wares, sugars, syrups, honey and table-top sweeteners, foods intended for 
particular nutritional uses as defined by Directive 2009/39/EC13 and non-alcoholic beverages, as per 
the proposed uses. The results are presented in Table 7. The mean intakes of 2’-FL in the total 
population, as reported in the FAIM tool, ranged from 24 to 60 mg/kg body weight per day in 
adolescents up to 96 to 204 mg/kg body weight per day in toddlers when the lower use levels were 
used, and ranged from 30 to 95 mg/kg body weight per day in adolescents and up to 320 to 666 
mg/kg body weight per day in toddlers when the maximum use levels were used (Table 7). High-level 
intakes ranged from 44 to 130 mg/kg body weight per day in adolescents and up to 213 to 452 mg/kg 
body weight per day in toddlers when the lower use levels were used, and ranged from 89 to 286 
mg/kg body weight per day in the elderly up to 822 to 1,928 mg/kg body weight per day in toddlers 
when the maximum use levels were used. 
The Panel notes that the EFSA FAIM tool has been developed as a screening tool for deriving chronic 
intake estimates for food additives for different population groups throughout several European 
countries. The tool is based on summary statistics of the EFSA Comprehensive database. The FoodEx 
classification used by this tool has been linked mainly to the level 2, and for few foods up to level 3, of 
the Food Classification System (FCS) as presented in Commission Regulation (EU) N° 1129/201114. 
Intake levels from all contributing food sources are obtained by adding the high-level (usually the 95th 
percentile) of exposure from the food category providing the highest estimate plus the estimated 
mean exposure values for the remaining categories. The underlying methodology of the FAIM tool 
generally leads to an overestimation of the estimated intakes as expressed by the EFSA instructions 
for the use of the FAIM tool (EFSA, 2012). 
Table 7:  Summary of estimated intakes of 2’-FL from proposed foods uses using the EFSA FAIM 
tool 
Population Ages Mean intakes (mg/kg body 
weight per day) 
High level intakes (mg/kg body 
weight per day) 
Lower use 
level 
Maximum use 
level 
Lower use 
level 
Maximum use 
level 
Toddlers 12 to 35 months 96–204 320–666 213–452 822–1928 
Children 3 to 9 years 53–153 75–263 104–363 172–682 
Adolescents 10 to 17 years 24–60 30–95 44–130 68–362 
Adults 18 to 64 years 22–87 35–152 51–163 90–304 
Elderly 65 years and older 19–83 30–158 36–147 89–286 
For the refined intake estimate based on UK individual consumption data, individual food codes 
representative of each proposed food use were taken from the food code list associated with the UK 
NDNS food consumption survey and grouped according to the proposed uses for the LNnT assessment 
presented in Table 6. The daily intake of 2’-FL was calculated at individual level, and represents 
projected 4-day averages for each individual from days 1 to 4 of NDNS data, in the UK population. 
High percentile intake estimates were derived from the distribution of these average amounts. Results 
are provided in Tables 8 and 9.  
In relation to all-user intakes, toddlers had the highest mean and 95th percentile intake of about 
1.67 g per day, whereas women of child-bearing age had the highest intakes at the 95th percentile of 
about 5 g per day (Table 8). On a body weight basis, toddlers were identified as having the highest 
                                                          
13 European Parliament and the Council of the European Union. Directive 2009/39/EC of the European Parliament and of the 
Council of 6 May 2009 on foodstuffs intended for particular nutritional uses. OJ L 124, 20.05.2009, p. 21–29. 
14 Commission Regulation (EU) No 1129/2011 of 11 November 2011 amending Annex II to Regulation (EC) No 1333/2008 of 
the European Parliament and of the Council by establishing a Union list of food additives. OJ L 295, 11.11.2011, p.1–177. 
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mean and 95th percentile intake of any population group of 120 and 247 mg/kg body weight per day, 
respectively (Table 9).  
Table 8:  Summary of the estimated daily intake of 2’-FL from proposed food categories  by 
different population groups in the UK, per person, based on data from NDNS 
Population 
group 
Age group 
(years) 
All-person 
consumption (g/day) 
All-user consumption 
(g/day) 
Mean 95th 
percentile 
% n Mean 95th 
percentile 
Toddlers 1–3 1.67 3.41 100 219 1.67 3.41 
Children 4–10 1.43 3.12 100 423 1.43 3.12 
Teenagers 11–18 1.31 3.13 99.7 451 1.31 3.14 
Women of child-
bearing age 
19–40 1.61 4.98 100 216 1.61 4.98 
Female adults 19–64 1.63 4.87 99.9 460 1.63 4.87 
Male adults 19–64 1.36 4.01 99.6 344 1.36 4.01 
Elderly adults 65 years and 
older 
1.35 3.60 99.8 223 1.35 3.61 
 
Table 9:  Summary of the estimated daily per kilogram body weight intake of 2’-FL from proposed 
food categories by different population groups in the UK, based on data from NDNS 
Population 
group 
Age 
group 
(years) 
All-person consumption 
(mg/kg body weight  
per day) 
All-user consumption 
(mg/kg body weight 
per day) 
Mean 95th 
percentile 
% n Mean 95th 
percentile 
Toddlers 1–3 120 247 100 219 120 247 
Children 4–10 58 135 100 423 58 135 
Teenagers 11–18 23 55 99.7 451 23 55 
Women of child-
bearing age 
19–40 24 75 100 216 24 75 
Female adults 19–64 24 74 99.9 460 28 74 
Male adults 19–64 16 50 99.6 344 16 50 
Elderly adults 65 years 
and older 
18 55 99.8 223 18 55 
 
One Member State noted that the intake estimates calculated by the applicant do not include the 
potential additional intake of 2’-FL from food supplements, as proposed in the application. According 
to the applicant, the most significant target group for food supplements will be women of child-
bearing age. Considering the highest estimated 95th percentile daily intake of 2’-FL at 5 g for women 
of child-bearing age plus the maximum intended daily intake from food supplements of 3 g, 2’-FL 
intakes in this population group could reach up to 8 g per day.  
In response to another comments from Member States, the applicant indicated that the proposed use 
levels of 2’-FL would result to intakes which are within the range of human milk on a per kg body 
weight basis. Table 5 shows that the high-intake scenario for infants would be about 670 mg/kg body 
weight per day, which is a level within the range of the estimated intake from breast milk. Table 9 
shows the highest 95th percentile intake for toddlers (247 mg/kg body weight per day), whereas for 
older age groups the estimates are lower. In his response the applicant also noted that the estimated 
daily intakes of 2’FL for older age groups also stay below the well-known levels of other non-digestible 
carbohydrates that can occasionally cause transient tolerability effects in older age groups (e.g. 
lactose (Mattar et al., 2012; Heaney, 2013), lactulose (Havenaar and Van Dokkum, 2001), inulin 
(Coussement and Franck, 2001), oligofructose (Coussement and Franck, 2001; Bali et al., 2015), and 
galacto-oligosaccharides (Torres et al., 2010)).  
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The Panel considers that the refined intake estimate based on UK individual consumption data is 
sufficiently conservative, as it is based on the assumption that all proposed food items consumed by 
an individual actually contain the NFI at the maximum specified level of use.  
 Information from previous exposure to the NFI or its source 3.4.
Human milk contains as its third largest solid component a fraction of oligosaccharides (Kunz and 
Rudloff, 1993; Bode, 2012; Newburg, 2013), which are known as human milk oligosaccharides 
(HMOs).  
2’-FL is one of the naturally occurring fucosylated oligosaccharides that are present in human milk 
(Erney et al., 2000; Chaturvedi et al., 2001a; Musumeci et al., 2006; Asakuma et al., 2008; Castanys-
Muñoz et al., 2013). However, 2’-FL is not detected in the milk of women (approximately 20 % of 
women) who do not express a specific enzyme, α-1,2-fucosyltransferase, in their mammary glands, 
which is responsible for fucosylating lactose at the 2’-O-position. This phenotype is referred to as the 
‘non-secretor’ phenotype and forms, together with the phenotype for another enzyme 
(α-1,4-fucosyltransferase, required to synthesise the so-called ‘Lewis’ antigens a and b), the basis for 
categorisation of human milk into four different phenotypes (Thurl et al., 1997, 2010; Coppa et al., 
2011). 
The applicant provided several publications on the 2’-FL content in human milk in relation to secretor- 
and Lewis-blood group status (Thurl et al., 1997; 2010, Coppa et al., 2011; Galeotti et al., 2012, 
2014), ethnicity (Erney et al., 2000; Musumeci et al., 2006), lactation period (Coppa et al., 1999; 
Erney et al., 2000; Sumiyoshi et al., 2003; Asakuma et al., 2008; Leo et al., 2010; Bao et al., 2013), 
preterm birth (Nakhla et al., 1999; Gabrielli et al., 2011), and in mature milk (Chaturvedi et al., 1997, 
2001a; Erney et al., 2000, 2001; Sumiyoshi et al., 2003; Morrow et al., 2004; Leo et al., 2010; Thurl 
et al., 2010; Asakuma et al., 2011; Coppa et al., 2011; Galeotti et al., 2012; Smilowitz et al., 2013; 
Hong et al., 2014). The concentration of 2’-FL in breast milk appears to depend on the lactation 
period, with higher levels reported in colostrum and decreased levels observed thereafter (Erney et 
al., 2000). Although the levels of 2’-FL decrease as lactation progresses, the levels of 2’-FL remain 
above 1 500 mg/L at 31 to 452 days post-partum (Coppa et al., 1999; Erney et al., 2000; Thurl et al., 
2010). 
According to the applicant the content of 2’-FL, from pooled data from different phenotypes milks, 
ranged between 1 100 and 4 260 mg/L in mature breast milk (Bao et al., 2013; Galeotti et al., 2014), 
with an average of approximately 2 350 mg/L. However, concentrations around 600 mg/L have also 
been reported (Sumiyoshi et al., 2003; Leo et al. 2010). Concentrations of up to 7 000 mg/L have 
been reported in the milk from secretor phenotype mothers (Galeotti et al., 2012; Gabrielli et al., 
2011). 
The applicant indicated that the content of 2’-FL in colostrum ranged from 1 120 to 4 900 mg/L 
(Musumeci et al., 2006; Bao et al., 2013); however, concentrations of 8 400 mg/L have also been 
reported from secretor phenotype mothers (Musumeci et al., 2006). 
Based on the levels of 2’-FL in mature breast milk and on a 6.5 kg infant drinking approximately 1 L of 
breast milk per day (Davies et al., 1994, Hester et al., 2012), the applicant indicated that the average 
intake of 2’-FL is approximately 170 to 660 mg/kg body weight per day. However, in infants from 
secretor mothers, the intake of 2’-FL from mature breast milk may be up to approximately 
1 150 mg/kg body weight per day. 
According to the applicant, for newborn infants, the average intake of 2’-FL from colostrum is 
approximately 80 to 360 mg/kg body weight per day based on a 3.4 kg newborn infant (WHO, 2014) 
drinking an average of 250 mL of breast milk per day during the first 5 days (Hester et al., 2012). 
However, in newborns from secretor mothers, the intake of 2’-FL from colostrum may be up to 
approximately 620 mg/kg body weight per day. 
2’-FL has been also detected in domestic farm animal milk, such as cow’s, sheep’s, camel’s, pig’s and 
goat’s milk (Urashima et al., 1994; Tao et al., 2010; Aldredge et al., 2013; Albrecht et al., 2014); 
however, data on the levels of 2’-FL in animal milk have not been reported. The amount of total 
oligosaccharides in domestic farm animal milks has been reported to be lower than those in human 
milk (Tao et al., 2009; Meyrand et al., 2013). 
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The Panel notes that the history of human exposure to 2’-FL is limited primarily to that of breast-fed 
infants. The Panel also notes that the proposed maximum intake level of the NFI by infants is within 
the range of 2′-FL levels found in mature breast milk, as reported in the literature, although at the 
high end of this range. 
 Nutritional information on the NFI 3.5.
2’-FL is, on average, the most abundant HMO in breast milk in the general population of breastfeeding 
women. However, approximately 20 % of breastfeeding women lack the enzyme in their mammary 
glands that is responsible for the biosynthesis of 2’-FL (referred to as non-secretors), and, thus, their 
milk is devoid of 2’-FL (and other 2’-O-fucosylated oligosaccharides). The majority (80 %) of 
breastfeeding women, however, produce milk with such a high level of 2’-FL that the substance 
remains the most abundant individual HMO when values obtained from different women with varying 
milk types are averaged or when samples from different women with varying milk types are pooled 
and an average obtained. 
The applicant proposes the addition of 2’-FL to IF, in order to bring IF and FOF closer to the 
composition of breast milk. The applicant also proposes the addition of 2’-FL to other food categories, 
such as bakery wares, sugars, syrups, honey and table-top sweeteners, PARNUTS (foodstuffs for 
particular nutritional uses) and beverages. 
The impact of uses other than IF would be comparable to the current use of fibre-type 
oligosaccharides (including laxative effects) which are added to a range of food products.  
The Panel considers that consumption of the NFI is not nutritionally disadvantageous. 
 Microbiological information on the NFI 3.6.
Microbiological limits, which also include microbial endotoxins, are presented in the product 
specifications (Table 1). The applicant provided analytical results for five batches which were 
compliant with the specifications (Table 2). 
The Panel considers that the microbiological information provided does not raise safety concern. 
 Toxicological information on the NFI 3.7.
3.7.1. Absorption, distribution, metabolism and excretion 
HMOs, including 2’-FL, are reported to be resistant to hydrolysis by digestive enzymes in in vitro 
studies (Engfer et al., 2000; Gnoth et al., 2000). 
HMO fermentation in the colon in infants who received a load of HMO (a purified oligosaccharide 
fraction from their mothers’ milk) was determined through a breath hydrogen test. The observations 
from this test suggest that HMOs, consumed as a load, are fermented in the colon (Brand-Miller et al., 
1995, 1998). 
The pattern and the amount of HMO in the faeces of breast-fed infants were compared with the 
pattern and amount of HMO in ingested breast-milk (Chaturvedi et al., 2001b; Coppa et al., 2001). 
These studies report that 40−50 % and 97 %, respectively, of the ingested amount of HMO is 
excreted unchanged in the faeces. 
Urinary excretion of HMO has been investigated in breast-fed infants. A bolus of 13C-labelled glucose 
or 13C-labelled galactose was given to lactating mothers in order to obtain 13C-labelled HMO, which 
could then be detected in the breast-fed infants’ urine (Obermeier et al., 1999; Rudloff et al., 2006, 
2012; Rudloff and Kunz, 2012; Dotz et al., 2014). Another study compared the amount of 
oligosaccharides in the urine of breast-fed infants with the oligosaccharides in their mothers’ milk 
(Chaturvedi et al., 2001b). These studies suggest that a small portion of HMO (approximately 1 to 
2 % of the ingested amount) is excreted unchanged in infants’ urine. Data from in vitro studies using 
the Caco-2 human intestinal epithelial cell model suggest that neutral HMOs (like 2’-FL) are 
transported across the intestinal epithelium by receptor-mediated transcytosis, as well as by 
paracellular pathways (Gnoth et al., 2001). In response to a comment from a Member State, the 
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applicant indicated that the use of 2’-FL in vulnerable individuals would occur under medical 
supervision, as required for foods for special medical purposes.  
Overall, the data indicate that a large proportion of the ingested HMO, including 2’-FL, reaches the 
large intestine and is either fermented by the intestinal microbiota or excreted in the faeces. 
There are no indications that the absorption of the NFI may differ from that of 2’-FL from breast milk, 
and the consumption levels of the NFI would likely be similar to those of 2’-FL from breast milk by 
infants.  
The Panel considers that the limited amount of the NFI that could be absorbed, as suggested by the 
above data, does not raise safety concerns. 
3.7.2. Genotoxicity 
The applicant provided three studies on the potential mutagenicity of 2’-FL, with a purity of 99 % 
(Coulet et al., 2014) and 96.9 % (in vitro micronucleus assay study). These studies were conducted in 
compliance with the Organisation for Economic Co-operation and Development (OECD) principles of 
GLP and the appropriate OECD test guidelines. 
In the bacterial reverse mutation assay (Ames test), five Salmonella typhimurium strains (TA98, 
TA100, TA1535, TA1537 and TA102) were exposed to 2’-FL, at levels up to 5 000 μg/plate, in the 
presence or absence of metabolic activation (S9-mix), using the plate-incorporation and pre-
incubation methods (OECD test guideline No 471; OECD, 1997a) (Coulet et al., 2014). No signs of 
cytotoxicity or precipitation were observed in any strain treated with 2’-FL in the presence or absence 
of S9-mix. Exposure to 2’-FL resulted in few significant increases in the number of revertants, which 
however, were not dose-related. Overall, there were no biologically significant increases in the 
number of revertants compared with the negative control, at any concentration of 2’-FL, either in the 
presence or absence of S9-mix. This study showed no mutagenicity of 2’-FL, with and without S9-mix, 
up to the highest tested concentration of 5 000 μg/plate. 
In the in vitro mammalian cell gene mutation test, L5178Y Tk+/– mouse lymphoma cells were 
incubated with 2’-FL for four hours, with or without S9-mix, and for 24 hours without S9-mix (Coulet 
et al., 2014). This study was conducted in compliance with the OECD test guideline No. 476 (OECD, 
1997b). No signs of precipitation or cytotoxicity were observed in the cells exposed to any 
concentration of 2’-FL. No statistically significant increases in the frequency of mutations were 
observed in cells treated with 2’-FL, with or without S9-mix. This study showed no mutagenicity of 
2’-FL, with or without S9-mix, up to the highest tested concentration of 5 000 μg/mL. 
In response to comments from Member States, the applicant provided the study report on an in vitro 
micronucleus assay with 2’-FL (OECD test guideline No 487, OECD 2014) (unpublished study report, 
2015a). 2’-FL was tested in human peripheral blood lymphocytes, with or without metabolic activation 
(S9-mix). The highest concentration tested of 2’-FL was 2 000 μg/mL. In the first experiment 2’-FL 
was tested for three hours with a 27-hour harvest time, with or without S9-mix, whereas in the 
second experiment, the exposure lasted 24 hours with a 24-hour harvest time, without S9-mix. 2’-FL 
did not induce a statistically significant increase in the number of mono- or binucleated cells with 
micronuclei, with or without S9-mix. This study showed neither clastogenicity nor aneugenicity of 
2’-FL, with or without S9-mix, up to the highest tested concentrations of 2 000 μg/mL.  
The Panel considers that the information provided does not raise safety concerns as regards the 
genotoxicity of the NFI.  
3.7.3. Repeated exposure toxicity studies 
The potential toxicity of the NFI was investigated in a sub-chronic (90-day) oral toxicity study in 
Wistar (Crl:WI(Han)) rats, which was preceded by a 14-day dose range-finding study (Coulet et al., 
2014). In all studies, synthetically produced 2’-FL with a purity of 99 % was used as the test material. 
Rat pups were used to adapt the standard OECD test guideline No 408 to the intended use of this NFI 
in infants (OECD, 1998a; Barrow, 2007). In both studies, fructo-oligosaccharides were given to a 
reference control group on the basis that they are used in IF. 
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In the non-GLP 14-day dose range-finding study with Wistar (Crl:WI(Han)) rats, 0 (vehicle control), 
2 000, 5 000, or 7 500 mg/kg body weight per day of 2’-FL were administered, by gavage, from 
post-natal day (PND) 7 until PND 20 (weaning) (Coulet et al., 2014). Liquid faeces and/or yellowish 
liquid faeces, which were accompanied by erythema in the urogenital region, were observed in most 
of the animals in the mid- and high-dose 2’-FL groups. Between days 0 and three, lower body weight 
gains were reported in the mid- and high-dose 2’-FL groups than in the control groups. At the end of 
the study, body weights were not different between the test and control groups. Based on the results 
of this study, the authors determined that the highest dose of 2’-FL considered suitable for the main 
study in rats should be lower than 7 500 mg/kg body weight per day. 
In the sub-chronic 90-day toxicity study with a 4-week recovery period, Wistar (Crl:WI(Han)) rat pups 
(PND 7) were administered, orally by gavage, 0 (water vehicle control), 2 000, 5 000, or 6 000 mg/kg 
body weight per day of 2’-FL for 90 consecutive days (Coulet et al., 2014). This study was conducted 
in compliance with the OECD principles of GLP and in accordance with OECD Test No. 408 (OECD, 
1998a, b).  
The cause of death of two animals (one male and one female in the high-dose 2’-FL group), which 
were found dead on day two, could not be determined by histopathological examination. 
A few statistically significant changes in organ weights were reported at the end of the administration 
period in the 2’-FL groups compared with the control group: a decrease in absolute adrenal weights in 
males in the mid- and high-dose 2’-FL groups; a decrease in relative adrenal weights in 2’-FL 
high-dosed males; an increase in relative heart weight in males in the 2’-FL mid-dose group; and a 
decrease in absolute brain weight and relative kidney weights in 2’-FL high-dosed females. 
Histopathological examination of the kidneys revealed a higher incidence of minimal cortical tubular 
epithelial cytoplasmic vacuolation in 2’-FL mid-dosed (6 out of 10) and high- dosed (3 out of 9) 
females at the end of the administration period than in the control group (1 out of 10). This could be 
associated with the decrease in relative kidney weight noted in females in the high-dose 2’-FL group. 
No cortical tubular epithelial cytoplasmic vacuolation was observed in males at the end of the 
administration period. In the recovery groups, minimal cortical tubular epithelial cytoplasmic 
vacuolation was seen in the 2’-FL high-dosed females (3 out of 5) and in the female control group 
(3 out of 5). No other compound-related histopathological findings were reported.  
A significant decrease in red blood cells, haemoglobin and packed cell volume were observed in 
female rats in the mid- and high-dose 2’-FL groups, compared with controls. A significant decrease in 
serum sodium levels was observed in males and females in the mid- and high-dose 2’-FL groups, 
compared with controls. A significant decrease in serum bilirubin was observed in the 2’-FL high-dosed 
males compared with controls, whereas a significant decrease in protein and globulin was observed in 
the 2’-FL mid- and high-dosed males compared with the controls. A slight increase in creatinine was 
observed in females in the mid- and high-dose 2’-FL groups compared with the control group. 
Based on the decrease in the relative kidney weight in the 2’-FL high-dosed female group, two 
unexplained deaths in the high-dose 2’-FL group and high-dosed female group, and the significant 
changes in the haematological and clinical blood parameters in the 2’-FL mid- and high-dosed group, 
the Panel considers that the no observed adverse effect level (NOAEL) is 2 000 mg/kg body weight 
per day. 
3.7.4. Human studies 
One Member State indicated the absence of studies on the safety of the NFI in infants aged 0-6 
months. In response to this comment and to a request by EFSA, the applicant provided an 
unpublished study report on a double-blind, randomised, controlled clinical trial on the effect of a 
combination of two oligosaccharides, 2’-FL and lacto-N-neotetraose (LNnT), in infants (unpublished 
study report, 2015b, d). The Panel notes that LNnT is subject to another application as a NFI which 
has been assessed in parallel with the safety assessment of 2’-FL (EFSA NDA Panel, 2015). A total of 
175 healthy, full-term infants (aged 0–14 days) were randomised to consume either a formula with 
added LNnT and 2’-FL (n = 88; 1.0–1.2 g/L of 2’-FL and 0.5–0.6 g/L of LNnT for reconstituted 
formula) or the same formula without oligosaccharides (n = 87) up to six months of age. The formula 
used was a standard whey-predominant starter IF with long-chain polyunsaturated fatty acids and 
without oligosaccharides (66.9 kcal/100 mL reconstituted formula, 1.9 g protein/100 kcal powder with 
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a whey:casein ratio of 2.5:1 (71.6 % whey and 28.4 % casein)). Exclusively breast-fed (BF) infants 
(beginning at three months of age) were included as a reference group. 
This study aimed to demonstrate a non-inferiority in weight gain between the two formula-fed groups 
up to four months of age (primary outcome). Differences in body weight, body length, head 
circumference, ‘digestive tolerance’, stool characteristics, behaviour patterns, formula intake, use of 
concomitant medications and adverse events between the two formula-fed groups were also 
investigated (secondary outcomes). 
The study showed that the weight gain in the test group was non-inferior to the weight gain in the 
control group in both the intention-to-treat (ITT) and per-protocol (PP) populations (n = 71 in the test 
formula group and n = 75 in the control formula group) (in the ITT population, −0.13 g/day (two-
sided 95 % confidence interval (CI) −1.63 to 1.37; p = 0.864); in the PP population, −0.30 g/day 
(two-sided 95 % CI −1.94 to 1.34; p = 0.715)). 
The mean weight, length, head circumference and BMI of infants aged 0–4 months were comparable 
with the corresponding World Health Organization (WHO) standard growth curves. No differences in 
mean weight, length, head circumference or BMI between groups were observed at any monthly visits 
(except for lengths at the 3-month visit).  
Stool consistency scores on the Bristol Stool scale were not significantly different between the test and 
control formula-fed groups, except for scores for 2-month-old infants in the test formula group, who 
had higher scores (i.e. softer stools) than infants who consumed the control formula. No significant 
difference was observed in the number of stools reported by parents between the two formula-fed 
groups. 
Overall, adverse events were not significantly different between the test and control formula-fed 
groups except for the incidence of bronchitis, which was significantly lower in infants in the 
intervention group than in those in the control group (odds ratio (OR) = 0.30; 95 % CI 0.11–0.73; 
p = 0.004). Antibiotic use was significantly lower in infants in the intervention group than in the 
control group (25.0 % vs. 41.4 %; OR = 0.47; 95 % CI 0.23–0.94, p = 0.025). 
Microbiota composition and the presence of pathogens in stools from infants of three months of age 
were reported. The alpha diversity of the microbiota of the BF group was significantly lower than the 
diversity of both formula groups, but the diversity of the test group was significantly reduced 
compared with the diversity of the control formula group and, therefore, closer to the BF group. An 
increase of Bifidobacterium, a decrease in Escherichia and unclassified Peptostreptococcaceae were 
reported for infants in the test formula group compared with the infants in the control formula group, 
showing proportions closer to the BF group. The number of infants with at least one detectable viral, 
bacterial or eukaryotic (protista) pathogen in stool samples was not statistically different between the 
two formula-fed groups. 
The Panel notes that this study showed no difference in growth in infants who consumed a formula 
added with the combination of 2’-FL and LNnT (at the concentrations tested in the study), compared 
with the control formula infants, and that the growth curves were comparable to the WHO standard 
curves. The Panel also notes that the results on stool and microbiota endpoints do not raise safety 
concerns.  
The Panel also notes that the concentration of the NFI in the infant formula studied in this trial, was 
only about half of the maximum level as proposed by the applicant. 
The applicant provided an unpublished study report on a placebo-controlled, double-blind, parallel, 
dose-response trial in 100 healthy adults (49 females, age range: 19–57 years) who were randomised 
into 10 groups (n = 10) to consume once daily either 2’-FL or LNnT alone (5, 10, 20 g of LNnT or 
2’-FL), or a combination of 2’-FL and LNnT (5, 10, 20 g as the total amount of the combination of 
2’-FL and LNnT at a ratio of 2:1), or placebo (glucose) for two weeks (unpublished study report, 
2015c). At the end of the intervention, a significant increase in nausea, rumbling, bloating, passing 
gas, diarrhoea, loose stools and urgency was reported for participants who consumed 20 g of 2’-FL 
compared with the placebo group. No difference to the placebo group was observed in the group with 
an intake of 5 and 10 g 2’-FL per day. At the end of the intervention, a significant increase in passing 
gas was reported for participants who consumed either 20 g or 10 g of LNnT, compared with the 
placebo group. Stool consistency scores on the Bristol Stool scale were not significantly different 
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between the interventions and placebo groups. In total, 44 participants reported adverse events, 
which could cover more than one symptom, and a total of 78 symptoms were recorded. 
Gas/flatulence was the most commonly reported adverse event, which was followed by stomach pain, 
diarrhoea and rumbling. A higher incidence of adverse events was observed in participants who 
consumed the single oligosaccharide at the highest dose tested (20 g). All adverse events were 
reported to be ‘mild’ and no serious adverse events were reported.  
 Allergenicity 3.8.
The manufactured 2’-FL contains no detectable proteins or peptides (see section 3.1) and so would 
not be anticipated to elicit any allergenic effect. 
The Panel considers that the likelihood of adverse allergic reactions to the NFI is low. 
4. Discussion 
The NFI is 2’-FL, a synthetic trisaccharide consisting of L-fucose, D-galactose and D-glucose, which is 
produced by using L-fucose and D-lactose as starting raw materials. The NFI is intended to be used in 
IF, FOF, foods for special medical purposes for infants and young children, and other foods for infants 
and young children. The NFI is also intended to be used in foods or food supplements for adults. 
Considering that 2’-FL is a naturally occurring trisaccharide that is present in human milk, the history 
of human exposure to 2’-FL is limited primarily to that of BF infants. The Panel notes that the 
proposed maximum intake level of the NFI by infants is within the range of 2′-FL levels found in 
mature breast milk, as reported in the literature, although at the high end of this range. 
A large proportion of ingested HMO, including 2’-FL, reaches the large intestine where it is either 
fermented by the intestinal microbiota or excreted unchanged in the faeces. There are no indications 
that the absorption of the NFI may differ from that of 2’-FL in breast milk and the consumption levels 
of the NFI would likely be similar to those of 2’-FL in breast milk for infants. Therefore, the Panel 
considers that the limited amount of the NFI that could be absorbed, as suggested by the data 
provided, does not raise safety concerns. 
Three studies were provided on the potential mutagenicity of the NFI: a bacterial reverse mutation 
assay (Ames test), an in vitro mammalian cell gene mutation test and an in vitro micronucleus assay. 
The Panel considers that the information provided does not raise safety concerns as regards the 
genotoxicity of the NFI. 
Based on observations from a sub-chronic 90-day toxicity study in rats, the Panel considers that the 
NOAEL is 2 000 mg/kg body weight per day. 
The applicant provided an unpublished study report on a double-blind, randomised, controlled clinical 
trial on the effects of a combination of two oligosaccharides, 2’-FL and LNnT, which are both under 
safety assessment as NFIs, in infants. This study on the combination of these two oligosaccharides 
reported that the weight gain of infants who consumed the formula with added 2’-FL and LNnT was 
not inferior to the weight gain of infants who were fed the control formula up to four months of age. 
Mean weight, length, head circumference and BMI in infants aged 0-4 months were comparable to the 
corresponding WHO standard growth curves. The results on stool endpoints and the reported changes 
in the composition of microbiota in infants consuming the combination of the two oligosaccharides do 
not raise safety concerns for the studied combination. The Panel considers that this study can be used 
to draw conclusions on the safety of this combination at the concentrations tested (i.e. 1.0–1.2 g/L of 
2’-FL and 0.5–0.6 g/L of LNnT for reconstituted formula). The Panel notes that the concentration of 
2’-FL in the infant formula studied in this trial, was only about half of the maximum level as proposed 
by the applicant. Based on EFSA food consumption data for infants, such a concentration of 2’-FL, 
would result in about 1.27 g per day and about 209 mg/kg body weight per day, respectively, at the 
95th percentile for a 3-months old infant weighing 6 kg.  
Taking into account that human milk contains a large number of oligosaccharides, which all together 
may have an important role for the development of microbiota in infants, the Panel considers that it 
cannot be excluded that the addition of a single oligosaccharide, i.e. 2’-FL alone, to IF (i.e. without 
LNnT) may have different effects on infants’ growth, microbiota, and stool frequency and consistency 
from those observed with the studied combination of the two oligosaccharides added to IF in the 
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provided study. The Panel therefore considers that no conclusion can be drawn from this infant study 
on the safety of the use of 2’-FL (without LNnT) added to IF. 
Noting that complementary feeding of infants and young children results in an increasingly diversified 
diet, the Panel considers that the potential impact of the addition of 2’-FL alone (without LNnT) or in 
combination with LNnT on the development of the microbiota diminishes with the proportion of 
complementary feeding and with age. According to the applicant’s intake estimate based on UK data, 
the 2’-FL intake at the 95th percentile for toddlers corresponds to about 3.4 g per day. On a mg per 
kg body weight per day basis, the respective value was 247. The Panel considers that 2’-FL alone or in 
combination with LNnT added at the proposed concentration in foods intended for children older than 
one year of age, does not raise safety concerns. The Panel considers that the concentration of 2’-FL 
as applied in the study in infants, should be used in IF, FOF and young-child formula (as described by 
EFSA (EFSA NDA Panel, 2014)). 
The applicant also provided an unpublished study report on a placebo-controlled, double-blind, 
parallel, dose-response trial in healthy adults who were randomised to consume either 2’-FL or LNnT, 
alone or in different combinations, or placebo for two weeks. This study showed that participants who 
consumed, daily, 20 g of 2’-FL reported a significant increase in nausea, rumbling, bloating, passing 
gas, diarrhoea, loose stools and urgency compared with the placebo group, while for subjects 
consuming 10 g of 2’-FL per day, these effects were not observed. Considering the highest estimated 
95th percentile daily intake of 2’-FL at 5 g for women of child-bearing age plus the maximum intended 
daily intake from food supplements of 3 g, daily 2’-FL intakes in this population group could 
theoretically result up to 8 g per day. The Panel notes that the intake estimate is based on the 
conservative assumption that all proposed food items consumed by an individual actually contain the 
NFI at the maximum specified level of use. 
5. Conclusions 
The Panel concludes that the novel food ingredient, 2'-O-fucosyllactose (2’-FL): 
 is safe for infants (up to one year of age) when added to infant and follow-on formulae, in 
combination with lacto-N-neotetraose (LNnT), at concentrations up to 1.2 g/L of 2’-FL and up 
to 0.6 g/L of LNnT, at a ratio of 2:1 in the reconstituted formulae; 
 is safe for young children (older than one year of age) when added to follow-on and 
young-child formulae, at concentrations up to 1.2 g/L of 2’-FL (alone or in combination with 
LNnT, at concentrations up to 0.6 g/L, at a ratio of 2:1); 
 is safe when added to other foods at the proposed uses and use levels. 
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Documentation provided to EFSA 
1. Letter from the European Commission to the European Food Safety Authority with the request 
for an opinion on 2'-O-fucosyllactose (2’-FL) as a novel food ingredient. Ref. SANCO/E6/SH/ks D 
(2015) 37263 Ref. Ares(2015)133857, dated 13 January 2015. 
2. Dossier ‘Application for the Approval of the Human-identical Milk Oligosaccharide 
2'-O-fucosyllactose (2’-FL) as a Novel Ingredient for Use in Infant and Follow-on Formulae and 
in Foods’, which was received by EFSA on 19 January 2015. Submitted by Glycom A/S. 
3. Initial assessment report carried out by the Food Safety Authority of Ireland: ‘Safety 
assessment of 2'-O-fucosyllactose (2’-FL)’. 
4. Member States’ comments and objections. 
5. Response by the applicant to the initial assessment report and the Member States' comments 
and objections. 
6. Additional data were provided by the applicant on 5 and 25 March 2015, 21 and 28 April 2015, 
18 May 2015, and 1, 5 and 12 June 2015. 
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Abbreviations 
2’-FL 2’-O-fucosyllactose 
BF breast-fed 
CI confidence interval 
DNSIYC diet and nutrition survey on infants and young children 
EMA European Medicines Agency 
FAIM food additive intakes model 
FOF follow-on formula(e) 
GLP good laboratory practices 
HACCP hazards analysis and critical control points 
HMO human milk oligosaccharide 
HPLC high-performance liquid chromatography 
IF infant formula(e) 
ITT intention-to-treat 
LNnT lacto-N-neotetraose 
NDNS national diet and nutrition survey 
NFI novel food ingredient 
NOAEL no observed adverse effect level 
OECD Organisation for Economic Co-operation and Development 
OR odds ratio 
PARNUTS foodstuffs for particular nutritional uses 
PND post-natal day 
PP per-protocol 
UHT ultra-high temperature 
WHO World Health Organization 
 
